Akari Therapeutics Reports H1 2026 Financial Results (8‑K Furnished)

What Happened
Akari Therapeutics Plc announced its results of operations and financial condition for the first half of the year ending December 31, 2026. The company issued a press release on August 13, 2026 reporting these interim financial results; that press release is furnished as Exhibit 99.1 to the Form 8‑K and is incorporated by reference.

Key Details

• Filing: Current Report on Form 8‑K (Item 2.02) filed August 13, 2026.
• Period covered: First half (H1) of the year ending December 31, 2026.
• Disclosure: Press release dated August 13, 2026 is furnished as Exhibit 99.1 to the 8‑K.
• The 8‑K furnishes results of operations and financial condition; investors should consult the press release for line‑item figures and narrative.

Why It Matters
This 8‑K is the company’s official notice to investors about its interim financial performance. The press release likely contains key metrics such as revenue, operating results, cash position and any management commentary that can affect valuation and near‑term expectations. Retail investors should read the attached press release (Exhibit 99.1) and the company’s other SEC filings to see the detailed numbers and assess any impact on the investment thesis.